Literature DB >> 21832836

Lower expression of tight junction protein 1 gene and increased FOXP3 expression in the small bowel mucosa in coeliac disease and associated type 1 diabetes mellitus.

Tamara Vorobjova1, Oivi Uibo, Ivi Ojakivi, Kaupo Teesalu, Marina Panarina, Kaire Heilman, Raivo Uibo.   

Abstract

BACKGROUND: The role of regulatory T cells expressing FOXP3 in the pathogenesis of coeliac disease (CD) and type 1 diabetes (T1D) has been reported. Recent data have placed special focus on the interplay between the intestinal barrier and immunoregulatory processes. We aimed to determine whether the expression of tight junction protein 1 (TJP1), which reflects small bowel mucosa permeability, is changed in CD and T1D.
METHODS: Transcription levels of TJP1 and FOXP3 genes were evaluated in the small bowel biopsies of 14 children with CD, 12 with CD and coexisting T1D and 40 controls using real-time PCR. Serum IgA and IgG to deamidated gliadin, bovine β-lactoglobulin, bovine α-casein and human tissue transglutaminase (tTG) were determined by ELISA.
RESULTS: The highest expression of FOXP3 mRNA was seen in patients with CD and T1D compared to patients with CD alone and controls (p = 0.02). In contrast, the lowest level of TJP1 mRNA expression was found in patients with CD and T1D (p = 0.01). The levels of IgA to deamidated gliadin and tTG were highest in patients with CD and T1D (p = 0.0001 and 0.01, respectively). The expression of FOXP3 mRNA correlated highly with the level of anti-gliadin IgA (p = 0.02) and anti-tTG IgA antibodies (p = 0.004).
CONCLUSION: The significant decline in TJP1 expression in CD patients, particularly in those with coexisting T1D, was accompanied by an increase in FOXP3 expression. This might reflect an attempt to maintain immune tolerance to counterbalance the loss of mucosal integrity in the small intestine in CD associated with T1D.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21832836     DOI: 10.1159/000324456

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  6 in total

1.  Are transglutaminase 2 inhibitors able to reduce gliadin-induced toxicity related to celiac disease? A proof-of-concept study.

Authors:  Tiina Rauhavirta; Mikko Oittinen; Rami Kivistö; Pekka T Männistö; J Arturo Garcia-Horsman; Zhuo Wang; Martin Griffin; Markku Mäki; Katri Kaukinen; Katri Lindfors
Journal:  J Clin Immunol       Date:  2012-08-10       Impact factor: 8.317

2.  Circulating Zonulin Correlates with Density of Enteroviruses and Tolerogenic Dendritic Cells in the Small Bowel Mucosa of Celiac Disease Patients.

Authors:  Tamara Vorobjova; Helerin Raikkerus; Lumme Kadaja; Ija Talja; Oivi Uibo; Kaire Heilman; Raivo Uibo
Journal:  Dig Dis Sci       Date:  2016-12-19       Impact factor: 3.199

3.  FABP4 and I-FABP Levels in Pregnant Women Are Associated with Body Mass Index but Not Gestational Diabetes.

Authors:  Tamara Vorobjova; Aili Tagoma; Ija Talja; Helis Janson; Anne Kirss; Raivo Uibo
Journal:  J Diabetes Res       Date:  2022-05-20       Impact factor: 4.061

4.  A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge.

Authors:  Daniel A Leffler; C P Kelly; H Z Abdallah; A M Colatrella; L A Harris; F Leon; L A Arterburn; B M Paterson; Z H Lan; J A Murray
Journal:  Am J Gastroenterol       Date:  2012-07-24       Impact factor: 10.864

Review 5.  Can exposure to environmental chemicals increase the risk of diabetes type 1 development?

Authors:  Johanna Bodin; Lars Christian Stene; Unni Cecilie Nygaard
Journal:  Biomed Res Int       Date:  2015-03-26       Impact factor: 3.411

Review 6.  Effects of diet on gut microbiota profile and the implications for health and disease.

Authors:  Yuan-Kun Lee
Journal:  Biosci Microbiota Food Health       Date:  2013-01-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.